Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,491 across all filing types
Latest filing 2022-03-31 Annual Report
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021
Annual Report Classification · 100% confidence The document is a detailed financial report containing consolidated final results for the year ended 31 December 2021, including comprehensive income statements, financial position statements, segment information, and notes on accounting policies. It references Hong Kong Financial Reporting Standards and includes extensive financial data and analysis for the full fiscal year. The presence of full financial statements and detailed disclosures indicates this is the official annual report of the company. The document is lengthy (15,000 characters) and contains substantive financial data, not merely an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-03-31 English
FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2021
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Final Dividend for the year ended 31 December 2021' and contains detailed information about the dividend amount, payment dates, record dates, ex-dividend dates, and share registrar details. It does not contain financial statements or management discussion but focuses solely on dividend declaration and payment logistics. The document length is 3181 characters, which is relatively short and consistent with a dividend announcement rather than a full financial report. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2022-03-29 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021' and contains detailed consolidated financial statements including profit or loss, comprehensive income, financial position, and notes to the consolidated financial statements. It includes extensive financial data, comparative figures for the previous year, and detailed notes on accounting policies and corporate information. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content matches the characteristics of an Annual Report or a comprehensive yearly financial report. It is not a brief earnings release or a simple announcement of results but a full set of financial statements and notes. Therefore, the document should be classified as an Annual Report (10-K equivalent). FY 2021
2022-03-29 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the Board of Directors about the date of a board meeting to approve the consolidated final results for the year ended 31 December 2021 and to consider a final dividend payment. It does not contain the actual financial results or detailed report but merely announces the meeting date and agenda. The document length is short (1523 characters) and it is clearly an announcement rather than the report itself. According to the rules, such announcements about board meetings to approve results and dividends fall under Regulatory Filings (RNS) as they do not contain substantive financial data or the report itself.
2022-03-21 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from the board of directors of 3SBio Inc. stating the date of a board meeting to consider and approve the annual results for the year ended 31 December 2021 and the payment of a final dividend. It does not contain the actual annual results or financial data, but merely announces the meeting where these will be considered. The document length is only 1379 characters, which is quite short and consistent with an announcement rather than a full report. According to the rules, such a notice of a board meeting to approve annual results is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the report itself or detailed financial data.
2022-03-16 English
VOLUNTARY ANNOUNCEMENT - 3SBIO'S LONG-ACTING ERYTHROPOIETIN SSS06 PROJECT HAS COMPLETED THE ENROLMENT OF THE FIRST SUBJECT FOR PHASE III CLINICAL STUDY
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the enrollment of the first subject in a phase III clinical study for a drug project. It is a press release-style update on clinical trial progress, not a financial report or regulatory filing. The text does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of voting results, board changes, or capital changes. The document is a company announcement about a clinical development milestone, which fits best under the category of a general Regulatory Filing (RNS) as it is a regulatory announcement that does not fit other specific categories.
2022-03-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.